Apogee Therapeutics Statistics
Share Statistics
Apogee Therapeutics has 58.51M shares outstanding. The number of shares has increased by 1.89% in one year.
| Shares Outstanding | 58.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 47.17M |
| Failed to Deliver (FTD) Shares | 12.40K |
| FTD / Avg. Volume | 2.67% |
Short Selling Information
The latest short interest is 7.97M, so 13.63% of the outstanding shares have been sold short.
| Short Interest | 7.97M |
| Short % of Shares Out | 13.63% |
| Short % of Float | 16.9% |
| Short Ratio (days to cover) | 13.25 |
Valuation Ratios
The PE ratio is -16.85 and the forward PE ratio is -15.09.
| PE Ratio | -16.85 |
| Forward PE | -15.09 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 3.73 |
| P/FCF Ratio | -18.89 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Apogee Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.38, with a Debt / Equity ratio of 0.
| Current Ratio | 19.38 |
| Quick Ratio | 19.38 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -24.35%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -24.35% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -922.91K |
| Employee Count | 91 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 21.09% in the last 52 weeks. The beta is 2.32, so Apogee Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.32 |
| 52-Week Price Change | 21.09% |
| 50-Day Moving Average | 48.42 |
| 200-Day Moving Average | 49.09 |
| Relative Strength Index (RSI) | 33.56 |
| Average Volume (20 Days) | 463.94K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -93.00M |
| Net Income | -83.98M |
| EBITDA | -83.98M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.66 |
Balance Sheet
The company has 118.32M in cash and 2.03M in debt, giving a net cash position of 116.28M.
| Cash & Cash Equivalents | 118.32M |
| Total Debt | 2.03M |
| Net Cash | 116.28M |
| Retained Earnings | -123.77M |
| Total Assets | 776.29M |
| Working Capital | 501.87M |
Cash Flow
In the last 12 months, operating cash flow was -74.76M and capital expenditures -167.00K, giving a free cash flow of -74.93M.
| Operating Cash Flow | -74.76M |
| Capital Expenditures | -167.00K |
| Free Cash Flow | -74.93M |
| FCF Per Share | -1.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
APGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.21% |
| FCF Yield | -3.25% |
Analyst Forecast
The average price target for APGE is $89, which is 125.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $89 |
| Price Target Difference | 125.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 40.73 |
| Piotroski F-Score | 1 |